

Serial Number 09/549,858

Amendments to the Specification

Please delete the paragraph at page 16, lines 10-16 and replace it with the following paragraph:

C1 It is desirable that the pH of solutions of compound 1 and other compounds of the invention in 5% dextrose or normal saline remain in a range near about pH 10 to provide for an acceptable use period in a clinical setting. Phosphate and glycine buffer systems were tested. Phosphate was found to be an effective buffer in the desired pH range, but, as indicated below, precipitated during freeze-drying of samples containing it; glycine-NaOH was an effective buffer and had a stabilizing effect on color change and may affect turbidity when evaluated with compound 1.

Amendments to the Claims

Please amend claims 4, 7, and 23 as noted on the attached sheet of paper. As required by 37 C.F.R. § 1.121(c), the amended claims are rewritten with all changes included on a paper attached to this response. Also attached is the compare copy of the claims, marked to show all of the changes relative to the previous version of the claims.

REMARKS

Claims 1 to 23 are pending. Claims 4, 7, and 23 have been amended herein. Claim 4 has been amended to prevent the need for an antecedent basis. Claim 7 has been amended to add a period in order to complete the claim sentence. Claim 23 has been amended to refer to the pharmaceutical formulation of claim 11 so that claim 11 provides sufficient antecedent basis for the claim. These amendments correct obvious typographical errors and support for these amendments can be found in the original claims. Accordingly, no new matter has been added by these amendments which are made to better define the claimed invention.

I. The claims are definite under 35 U.S.C. § 112, second paragraph

Claims 4, 7-10, and 23 are rejected for a variety of reasons under 35 U.S.C. § 112, second paragraph, as indefinite. The rejections are discussed in turn below.